Maintenance of response through up to 3-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial - 22/08/19
Kristian Reich, MD, Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany; Michael Song, MD, Janssen Research & Development, LLC, Spring House, PA; Bruce Randazzo, MD, Janssen Research & Development, LLC, Spring House, PA; Shu Li, PhD, Janssen Research & Development, LLC, Spring House, PA; Yaung-Kaung Shen, PhD, Janssen Research & Development, LLC, Spring House, PA; Chenglong Han, PhD, Janssen Research & Development, LLC, Spring House, PA; April Armstrong, MD, Keck School of Medicine, University of Southern California, Los Angeles, CA; Peter Foley, MD, University of Melbourne, St. Vincent’s Hospital, Melbourne and Skin & Cancer Foundation Inc, Carlton, VIC, Australia; Kenneth B. Gordon, MD, Medical College of Wisconsin, Milwaukee, WI
Le texte complet de cet article est disponible en PDF. Supported 100% by Janssen Research & Development. |
Vol 81 - N° 4S1
P. AB236 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?